Gene · 10644
Papers3,666
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 3,666
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Risk Score Model Based on Drug-Sensitivity-Related Genes Has the Potential to Predict Oral Squamous Cell Carcinoma Prognosis. | Oral Health Prev Dent | 2025 | 40762677 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
| Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. | Eur J Med Res | 2025 | 40760677 | PubTator, text mining | PubMed |
| FTO-mediated the destabilization of RASGRF1 mRNA impedes thyroid cancer progression and suppresses macrophage M2 polarization. | Cell Biol Toxicol | 2025 | 40760370 | PubTator, text mining | PubMed |
| Identify new pseudogene RPL7P1-oriented network as a drug target against infections pre-existing diabetes. | Integr Biol (Camb) | 2025 | 40748624 | PubTator, text mining | PubMed |
| A Study to Evaluate the Potential Role and Clinical Application Value of Long Noncoding RNA CASC Family Members in Colorectal Cancer Based on Transcriptomic Data. | Int J Genomics | 2025 | 40746360 | PubTator, text mining | PubMed |
| The m6A modification reader protein IGF2BP2 regulates ferroptosis in nasopharyngeal carcinoma cells by stabilizing CP expression via an m6A-dependent mechanism. | Biochem Biophys Res Commun | 2025 | 40743989 | PubTator, text mining | PubMed |
| M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges. | Front Oncol | 2025 | 40740874 | PubTator, text mining | PubMed |
| Hsa_circ_0020491 promotes polycystic ovary syndrome by interacting with IGF2BP2 through regulation of granular cell autophagy and mitochondrial dysfunction. | Gynecol Endocrinol | 2025 | 40739999 | PubTator, text mining | PubMed |
| Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. | Signal Transduct Target Ther | 2025 | 40739089 | PubTator, text mining | PubMed |
| RNA m6A modification: a key regulator in normal and malignant processes. | Cell Investig | 2025 | 40734692 | PubTator, text mining | PubMed |
| PDK1-dependent metabolic reprogramming regulates stemness and tumorigenicity of osteosarcoma stem cells through ATF3. | Cell Death Dis | 2025 | 40730548 | PubTator, text mining | PubMed |
| METTL3 blocked the progression of diabetic retinopathy through m6A-modified SOX2. | Open Med (Wars) | 2025 | 40727611 | PubTator, text mining | PubMed |
| Hsa_circ_0081111 promotes the proliferation and metastasis of non-small cell lung cancer by regulating IGF2BP2-mediated stability of Slug mRNA. | Exp Cell Res | 2025 | 40712910 | PubTator, text mining | PubMed |
| LncRNA TMEM99 Complexes with IGF2BP2 to Inhibit Autophagy in Lung Adenocarcinoma. | Adv Sci (Weinh) | 2025 | 40704413 | PubTator, text mining | PubMed |
| circFUT8 promotes proplatelet formation by interacting with IGF2BP2 and stabilizing TNS1 mRNA in megakaryocytes. | Blood | 2025 | 40700582 | PubTator, text mining | PubMed |
| ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming. | Front Oncol | 2025 | 40697388 | PubTator, text mining | PubMed |
| WITHDRAWAL: METTL3-Mediated TIM1 Promotes Macrophage M1 Polarization and Inflammation Through IGF2BP2-Dependent Manner. | J Biochem Mol Toxicol | 2025 | 40665792 | PubTator, text mining | PubMed |
| IGF2BP2 alleviates ulcerative colitis by inhibiting MEK1/2 and ERK1/2 signaling pathways in intestinal epithelial cells via m6A-dependent stabilization of LGI4 mRNA. | Int Immunopharmacol | 2025 | 40663812 | PubTator, text mining | PubMed |
| Mechanism of RBM15 in high glucose-induced pyroptosis of renal tubular epithelial cells. | Clin Exp Nephrol | 2025 | 40658167 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10644/papers?page=12